title: MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2.
abstract: Our previous studies have revealed that miR-148a is downregulated in pancreatic cancer. Bioinformatics analysis has shown cholecystokinin-B receptor (CCKBR) and B cell lymphoma (Bcl-2) to be potential targets of miR-148a. But the pathophysiologic role of miR-148a and its relevance to the growth and development of pancreatic cancer are yet to be investigated. The purpose of this study is to elucidate the molecular mechanisms where miR-148a acts as a tumor suppressor in pancreatic cancer. Our results showed significant downregulation of miR-148a in 28 pancreatic cancer tissue samples and five pancreatic cancer cell lines, compared with their non-tumor counterparts by qRT-PCR. MiR-148a was found to not only inhibit the proliferation of pancreatic cancer cells (PANC-1 and AsPC-1) in vitro by MTT assay and colony formation assay, but also to promote cells apoptosis in vitro by Annexin V-FITC apoptosis detection and caspase activity assay. Using western blot and luciferase activity assay, CCKBR and Bcl-2 were identified as targets of miR-148a. Moreover, we also found that the expression of Bcl-2 lacking in 3'UTR could abrogate the pro-apoptosis function of miR-148a. These findings suggest the importance of miR-148a's targeting of CCKBR and Bcl-2 in the regulation of pancreatic cancer growth and apoptosis.
authors: Department of Emergency, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Road, Zhengzhou, Henan, 450052, China.
authors: Rui
authors: R
authors: Zhang
authors: Min
authors: M
authors: Li
authors: Wenqiao
authors: W
authors: Zang
authors: Xudong
authors: X
authors: Chen
authors: Yuanyuan
authors: Y
authors: Wang
authors: Ping
authors: P
authors: Li
authors: Yuwen
authors: Y
authors: Du
authors: Guoqiang
authors: G
authors: Zhao
authors: Li
authors: L
authors: Li
mesh_terms: D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000235:genetics*; D020029:Base Pairing; D001483:Base Sequence; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics* / Q000378:metabolism; D034622:RNA Interference; D043887:Receptor, Cholecystokinin B / Q000235:genetics* / Q000378:metabolism
chemical_list: C550570:MIRN148 microRNA, human; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2; D043887:Receptor, Cholecystokinin B
references: Cell Mol Life Sci. 2004 May;61(9):1042-68
references: 15112052
references: Cancer Lett. 2008 May 18;263(2):302-11
references: 18258354
references: Oncogene. 2007 Feb 26;26(9):1324-37
references: 17322918
references: Regul Pept. 2010 Jun 8;162(1-3):52-60
references: 20144901
references: J Biol Chem. 2000 Oct 13;275(41):32122-8
references: 10913157
references: Gastroenterology. 2002 Feb;122(2):428-37
references: 11832457
references: Gastroenterology. 2005 Jun;128(7):1965-83
references: 15940630
references: Nat Rev Cancer. 2009 Jul;9(7):501-7
references: 19550425
references: Nat Med. 2007 May;13(5):613-8
references: 17468766
references: Int J Cancer. 2008 Aug 15;123(4):958-66
references: 18528859
references: Int J Cancer. 2006 Dec 15;119(12):2724-32
references: 16998832
references: Gut. 2000 Dec;47(6):820-4
references: 11076881
references: Cancer Res. 2005 Jul 1;65(13):5554-60
references: 15994927
references: Oncogene. 2006 Jul 27;25(32):4421-8
references: 16547500
references: Trends Pharmacol Sci. 2011 Apr;32(4):201-5
references: 21397342
references: Am J Pathol. 2004 Dec;165(6):2135-45
references: 15579455
references: Breast Cancer Res Treat. 2006 Sep;99(1):77-83
references: 16541314
references: Pancreas. 2005 Nov;31(4):317-24
references: 16258364
references: World J Gastroenterol. 2005 Jun 7;11(21):3217-21
references: 15929170
references: Int J Oncol. 2006 Dec;29(6):1429-35
references: 17088981
references: Br J Pharmacol. 2005 Feb;144(3):338-48
references: 15655524
references: Br J Cancer. 2006 Mar 27;94(6):776-80
references: 16495913
references: Science. 2005 Sep 2;309(5740):1519-24
references: 16141061
references: J Clin Invest. 2009 Sep;119(9):2691-701
references: 19652364
references: Cancer Res. 2000 Oct 15;60(20):5902-7
references: 11059789
references: Mol Cancer. 2010 Jan 26;9:16
references: 20102618
references: Aliment Pharmacol Ther. 2000 Oct;14(10):1231-47
references: 11012467
references: Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G798-805
references: 18719002
references: Mol Cancer Ther. 2006 Jun;5(6):1387-95
references: 16818496
references: Lab Invest. 2006 Oct;86(10):1037-51
references: 16894354
references: Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R17-29
references: 16651366
references: Mol Cell Biochem. 2010 Oct;343(1-2):133-41
references: 20559691
references: Am J Physiol Gastrointest Liver Physiol. 2012 Jun 1;302(11):G1244-52
references: 22442157
references: Eur J Cancer. 2005 Oct;41(15):2213-36
references: 16146690
references: Cancer Biol Ther. 2012 Feb 1;13(3):164-74
references: 22277584
references: Cell. 2004 Jan 23;116(2):281-97
references: 14744438
references: Int J Cancer. 2010 Feb 15;126(4):864-75
references: 19697327
references: Cancer Res. 2006 May 15;66(10):4991-5
references: 16707418
references: Hepatobiliary Pancreat Dis Int. 2002 May;1(2):306-8
references: 14612291